Health Economics›Multiple myeloma›First-line therapy

First-line therapy

Multiple myeloma · 24 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
BiRd Variant #01	—	R 11 990	28d	23.0 mo	—	26	R 311 736 PFS proxy	1
Lenalidomide and Dexamethasone (RD) Variant #01	—	R 5 879	28d	—	—	—	—	—
DECA Variant #01	—	R 5 615	21d	—	—	—	—	—
C-VAMP Variant #01	—	R 4 572	21d	—	—	—	—	—
VAMP Variant #04	—	R 3 905	21d	—	—	—	—	—
VAD Variant #06	—	R 1 864	28d	—	—	—	—	—
VBMCP/VBAD Variant #01 Partial	—	R 1 795	35d	—	—	—	—	—
Melphalan and Dexamethasone Variant #05	—	R 1 487	42d	—	~45.5 mo	—	—	2
DEX-IFN Variant #01	—	R 1 389	42d	—	—	—	—	—
Dexamethasone monotherapy Variant #11	—	R 1 389	35d	—	—	—	—	—
VMCP/VCAP Variant #01	—	R 892	21d	—	—	—	—	—
VMCP/VBAP Variant #01 Partial	—	R 635	21d	—	—	—	—	—
CVP Variant #01	—	R 585	21d	—	—	—	—	—
mCOP/MP Variant #01	—	R 519	42d	—	44.0 mo	—	—	—
ABCM Variant #01 Partial	—	R 440	42d	—	32.0 mo	—	—	—
VMCP Variant #01	—	R 416	30d	—	47.6 mo	—	—	1
VBMCP Variant #01 Partial	—	R 357	35d	—	—	—	—	—
Melphalan and Prednisone (MP) Variant #18	—	R 206	42d	—	29.1 mo	—	—	2
MP (Prednisolone) Variant #01	—	R 75	28d	—	—	—	—	—
Melphalan monotherapy Variant #01	—	R 71	42d	~50.0 mo	—	~37	~R 2 636 PFS proxy · indirect	4
Cyclophosphamide monotherapy N/A - secondary systemic drug	—	R 60	28d	—	~15.8 mo	—	—	1
VBMC Partial	—	—	—	—	—	—	—	—
M-DEX Partial	—	—	—	—	—	—	—	—
EDAP Partial	—	—	—	—	—	—	—	—

24 of 24 regimens shown